Glucagon & Pancreas: A Technical Pros and Cons Analysis
Published: July 15, 2026 03:03
Author: Francesca Garcia
Abstract: This technical analysis evaluates glucagon’s role in pancreatic physiology and its commercial peptide applications. Pros include potent glycemic control in hypoglycemia and emerging dual-agonist therapies (e.g., GLP-1/glucagon). Cons involve instability, short half-life, and manufacturing complexity. Market trends show 12.4% CAGR (2024–2030) driven by obesity and diabetes. Leading brands (Novo Nordisk, Zealand Pharma) differ in purity (>98%) and delivery systems. Key selection criteria: GMP-certified facilities, cold-chain logistics (2–8°C), and third-party HPLC purity certificates. The sector demands rigorous quality control for therapeutic efficacy.